Abstract Aims/hypothesis: Immunological and genetic markers can be used to assess risk of developing type 1 diabetes prior to the onset of clinical symptoms. Autoantibody-positive relatives of patients with type 1 diabetes are at increased risk for disease, while the presence of HLA DQA1*0102/DQB1*0602 is thought to confer protection. Using the unique population identified by the Diabetes Prevention Trial-Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes. Methods: We described metabolic and immunological characteristics of islet cell cytoplasmic autoantibodies-positive relatives with DQB1*0602 identified as part of DPT-1. Results: We found that 32% of DQB1*0602-positive relatives identified through the DPT-1 had abnormalities of glucose tolerance despite the fact that only 19% had multiple type 1 diabetes-associated autoantibodies and only 13% had abnormal insulin secretion, markers typically associated with the disease. In addition, these markers were not associated with abnormal glucose tolerance. In contrast, the DQB1*0602-positive relatives had elevated fasting insulin (117±10 pmol/l) and homeostasis model assessment of insulin resistance (HOMA-R) (4.90±0.5) values, which are more commonly associated with type 2 diabetes. The later marker of insulin resistance was associated with glucose tolerance status. Conclusions/ interpretation: Our data indicate that DQA1*0102/ DQB1*0602 relatives identified through DPT-1 have a high frequency of abnormal glucose tolerance and a disease phenotype with characteristics of type 1 and type 2 diabetes. Thus, multiple pathways to abnormal glucose tolerance are present within families of these type 1 patients.
Introduction
Type 1 diabetes is an autoimmune disease whose natural history and pathogenesis can be assessed prior to symptomatic onset through a combination of genetic and humoral immune markers. Indeed, genes from the HLA DR and DQ region confer both disease susceptibility and resistance, while autoantibodies against various islet cell autoantigens normally mark ongoing anti-beta-cell immunity and increased risk of developing the disease. We previously described a population of autoantibody-positive relatives of persons with type 1 diabetes who have the HLA haplotype DQA1*0102/DQB1*0602 [1] . Though the presence of autoantibodies usually suggests an increased risk for type 1 diabetes, the presence of DQA1*0102/ DQB1*0602 is thought to impart protection from type 1 diabetes, since it is only present in approximately 1% to 3% of Caucasian patients with the disease, compared with a 25% frequency in the general population [2] [3] [4] [5] [6] [7] . In addition, previous reports analysing a small number of similarly autoantibody-positive relatives led to the concept that the presence of DQA1*0102/DQB1*0602 affords dominant protection from type 1 diabetes [8] [9] [10] .
Based on the ability to use genetic and autoantibody markers to assess future risk for type 1 diabetes, the Diabetes Prevention Trial-Type Diabetes (DPT-1) was established to observe whether antigen-specific therapies could delay the onset of disease in nondiabetic relatives of individuals with type 1 diabetes who were deemed at increased risk of the disease [11] . As part of this screening process, the DPT-1 identified a large number of DQB1*0602-positive subjects. Using data from an initial 100 subjects, we previously confirmed by sequence analysis that these subjects were in fact DQB1*0602 [12] and reported that these relatives were much less likely to be confirmed positive for islet cell cytoplasmic autoantibodies (ICA), to have multiple antibodies, and to have low firstphase insulin release [1] . In this report, we extend our previous cross-sectional observations and present additional autoantibody and metabolic data that address the natural history of these two parameters in this population of subjects. Specifically, the aim of our study was to determine whether DQB1*0602-positive relatives identified through the DPT-1 are protected from type 1 diabetes.
Materials and methods
These investigations were approved by the institutional review boards at participating centres prior to study initiation and informed consent was obtained from all individuals and/or their parent/guardian prior to participation.
Subjects
An overview of subject selection and treatments is given in Fig. 1 .
Antibody-positive DQA1*0102/DQB1*0602 subjects From February 1994 through to May 2000, the DPT-1 screened more than 81,000 first-and second-degree relatives of patients with type 1 diabetes, of whom 3.6% were identified as positive for ICA [11] . All individuals found ICA-positive at screening were offered the opportunity to participate in further studies including that of HLA assessment. Autoantibody-positive relatives identified with DQA1*0102/DQB1*0602 were excluded from further participation in the DPT-1 because their risk of developing type 1 diabetes was deemed too low for a trial whose principal goal was to assess therapeutic interventions. From 1994 to 2001 DPT-1 screening identified 225 ICA-positive relatives with the DQA1*0102/DQB1*0602 haplotype. As part of the DPT-1, these subjects were notified that they had a low risk for type 1 diabetes.
The ancillary study, which formed the basis of this current report, began in June 1999. Our original study design planned to recruit 60 subjects. Of the 135 subjects contacted, 68 agreed to travel to Seattle, Washington, to undergo OGTT, IVGTT, and sampling for additional autoantibody markers often associated with type 1 diabetes. The mean age of these subjects at the time of OGTT testing was 21.0±1.4 years (range 5.6-48.5 years). The male to female ratio was 1:1. There were 52 first-degree relatives of individuals with type 1 diabetes (22 siblings, 23 offspring, 7 parents), the remainder were second-degree relatives. Of the subjects studied, 58 were non-Hispanic whites, 3 were blacks, 2 Hispanics, 1 American Indian and 1 Pacific Islander. In three subjects ethnicity was unspecified. The ethnicity, sex, age, and relationship to proband of this group did not differ from the remaining 157 DQA1*0102/DQB1*0602 subjects identified, who did not participate in this ancillary study.
Each of these 68 subjects had a first-or second-degree proband with type 1 diabetes which made them eligible for DPT-1 screening. HLA typing was performed on 66 of these type 1 diabetic probands.
Autoantibody-positive DQA1*0102/DQB1*0602-negative subjects Data from relatives who did not have HLA DQA1*0102/DQB1*0602 and which had been obtained as part of the DPT-1 were used for comparative purposes. Subjects who underwent OGTT as part of DPT-1 were matched for age within 5 years and sex in a 2:1 ratio with the prospectively followed subjects (n=135). There were 124 non-Hispanic whites, 2 blacks, 5 Hispanics, 1 Asian/ Pacific Islander, and 4 of other or unspecified ethnicity in "0602" ancillary study;n=68
IVGTT, OGTT, mIAA, GADA, ICA512, ICA Age and sex matched DQA1*0102/B1*0602-negative population used for "0602" ancillary study, n=135 Fig. 1 Source of subjects and data. Boxed text and solid arrows delineate DPT-1 protocol visits and tests. Unboxed text and dotted arrows delineate the ancillary study populations and data this matched cohort. This distribution was no different than that of the DQA1*0102/DQB1*0602 subjects (p=0.5).
Autoantibodies
Islet cell cytoplasmic autoantibodies Islet cell cytoplasmic autoantibodies for DPT-1 were determined by immunofluorescence assay on frozen sections of human pancreas in the DPT-1 ICA Core Laboratories (Gainesville, FL, USA; February 1994 to September 1997; New Orleans, LA, USA; September 1997 to January, 1999; Gainesville, FL, USA; January 1999 to 2001). ICA values of 10 or more Juvenile Diabetes Foundation (JDF) units were considered positive. In the 1995 Immunology of Diabetes Society workshop, this ICA assay had a specificity of 100% and a sensitivity of 74.4% for new-onset type 1 diabetes patients who were younger than 30 years of age [13] .
GADA, ICA512A and mIAA Autoantibodies against glutamic acid decarboxylase (GADA), ICA512 (ICA512A), insulin (micro IAA [mIAA]) were determined in Denver, CO, USA, on DPT-1 samples as part of a DPT-1 ancillary study. As previously described, a combined GADA and ICA512A radioassay was performed [14] . Labelled recombinant GAD65 and ICA512 were produced by in vitro transcription/translation with differential labelling ([
H] GAD65 and [
35 S]ICA512). The levels of both autoantibodies were expressed as an index value. The interassay coefficients of variation were 6% and 9.6% for GADA and ICA512A respectively. The upper limits of normal (0.032 for GADA; 0.049 for ICA512A) were established as the 99th percentile for GADA and for ICA512A from receiver operating characteristics curves in 198 healthy control subjects and 50 patients with new-onset type 1 diabetes. In the 2002 Diabetes Antibody Standardization Program (DASP) proficiency testing, the sensitivity for the GADA assay was 90% with a specificity of 93%. The sensitivity for the ICA512A assay was 62% with a specificity of 99%. The mIAA assay is distinct from the IAA assay used as entry criteria in DPT-1. The interassay coefficient of variation for the mIAA assay was 12%. In the aforementioned DASP testing, the sensitivity for the mIAA assay was 62% with 98% specificity.
Measures of beta cell function
Oral glucose tolerance Oral glucose tolerance tests were performed after an overnight fast and insertion of an i.v. catheter in an antecubital vein. Samples were drawn at −10 and 0 min. Oral glucose was administered in a dose of 1.75 g/kg body weight to a maximum of 75 g as a solution in flavoured water and consumed within 5 min. Blood samples were obtained at 30, 60, 90 and 120 min after glucose consumption to determine glucose, insulin and Cpeptide levels. The American Diabetes Association's definitions were used to define categories of glucose tolerance on OGTT [15] . Thus, normal glucose tolerance was defined as fasting glucose lower than 6.1 mmol/l and 2-h glucose 7.8 mmol/l or less. Abnormal glucose tolerance included subjects with diabetes (mean fasting glucose ≥7 mmol/l and/or 2-h value ≥11.1 mmol/l), IFG (fasting value between 6.1 and 7.0 mmol/l with a 2-h value <7.8 mmol/l), or IGT (2-h value between 7.8 and 11.0 mmol/l).
First-phase insulin secretion Intravenous glucose tolerance tests were performed according to the ICARUS protocol [16, 17] . After an overnight fast and insertion of an i.v. catheter in an antecubital vein, samples were drawn at −10 and −4 min. Fasting insulin was determined from a mean of these two baseline values. A solution of 25% glucose (0.5 g/kg; maximum 35 g) was then administered i.v. over a 3-min period. After the infusion of glucose, samples were drawn at 1, 3, 5, 7 and 10 min. Insulin and glucose were measured in the DPT-1 Beta Cell Function Core Laboratory (Seattle, WA, USA). The insulin values at 1 and 3 min were added to calculate a measure of firstphase insulin release (FPIR). The tenth percentile of normal controls for siblings and offspring over age 8 years was 600 pmol/l. The tenth percentile of normal controls for siblings and offspring under age 8 years and the first percentile for parents was 360 pmol/l. These values were determined from intravenous glucose tolerance test studies of 224 nondiabetic individuals aged 4 to 45 years of age and were used as the thresholds for eligibility for the parenteral insulin intervention trial [11] .
Homeostasis model assessment of beta cell function (HOMA-B) This index of resting beta cell function correlates with beta cell secretion measured by intravenous glucose tolerance and was calculated as follows: fasting insulin (μU/ml)×20/(fasting glucose [mmol−3.5]) [18, 19] . HLA typing Samples for HLA typing were obtained during the first staging visit for ICA-positive relatives. HLA typing was performed at the DPT-1 HLA Core Laboratory (Denver, CO, USA). HLA-DQA1 and DQB1 alleles were typed using PCR and sequence-specific oligonucleotide probes [21, 22] . HLA DQA1*0102, DQB1*0602-positive and -negative control samples were included in all assays.
Measures of insulin resistance

Statistical analysis
Categorical variables were compared between those with and without DQA1*0102/DQB1*0602 by the Pearson's chi-square test or Fisher's exact test (depending on the number of individuals per cell). Continuous variables were compared by the t-test or Wilcoxon rank-sum test (depending on the distribution of the variable). Values for HOMA-B and HOMA-R were log transformed for analysis. With the exception of data in Table 2 , tests of significance were two tailed and a p value of 0.05 was considered significant. In Table 2 , since multiple comparisons were done, none of the differences between variables are considered significant. Statistical analyses were performed using SAS software (SAS Institute, Cary, NC, USA).
Results
Immunological and genetic assessments DQA1*0102/ DQB1*0602 ICA-positive subjects had GADA, ICA512A, and mIAA autoantibody testing performed on either their initial DPT-1 screening sample or on a subsequent sample obtained as part of the prospective study. Using data from the first available result, 12/68 (17.7%) subjects had GADA, 3/68 (4.4%) subjects were ICA512A-positive, and 4/67 (6.0%) were mIAA-positive.
HLA typing revealed that 2/66 (3%) of the subjects have probands with type 1 diabetes who also have the DQB1*0602 haplotype. This was not different than the frequency of DQB1*0602 seen among a general population of people with diabetes 49/1664 (2.9%) or among GADA or ICA512A-positive individuals with diabetes (14/970 [1.4%]; G. Eisenbarth, unpublished observation).
Metabolic assessments OGTT results consistent with the diagnosis of diabetes were found in 2/68 (2.9%) of subjects. Results in 19 subjects indicated IGT, and one subject had IFG. Thus, 22/68 (32.4%) of DQB1*0602 relatives had abnormalities of glucose tolerance, significantly more than the 23/135 (17.0%) of relatives without DQB1*0602 (p=0.012) ( Table 1) . Of these 23 glucoseintolerant relatives without DQA1*0102/DQB1*0602, 4 had OGTT results consistent with the diagnosis of diabetes, 3 had IFG, and 16 had IGT.
With regard to measures associated with insulin resistance, the DQB1*0602 subjects had a mean BMI of 24.2 ±0.9 kg/m 2 , a HOMA-R of 4.90±0.5, and fasting insulin of 117±10 pmol/l. Of DQB1*0602-positive subjects, 23/68 (33.8%) had fasting insulin values greater than 120 pmol/l. Both the HOMA-R and the fasting insulin values in the subjects with DQB1*0602 were significantly greater than in the DQB1*0602-negative controls, while the mean BMI was not different between groups (Table 1) .
As for measures reflective of beta cell function, the mean HOMA-B value was 219.2±15.2 in DQB1*0602-positive subjects. This was not different from those without DQA1*0102/DQB1*0602 (HOMA-B 191.5±9.8, p=0.1). The mean FPIR of the study subjects with DQA1*0102/DQB1*0602 was 1376±107, with only 9/68 (13.2%) having FPIR below threshold. Among the 59 subjects with intact FPIR, 18 or 30.5% had abnormal glucose tolerance.
There was no relationship between the presence of autoantibodies, the occurrence of a high-risk second haplotype (0301/0302 or 0501/0201), or low FPIR and the existence of abnormal glucose tolerance, while those with abnormal glucose tolerance had higher HOMA-R values than those with normal glucose tolerance, though the latter was probably not significant due to multiple comparisons ( Table 2) . 
Discussion
This study is the first to demonstrate that DQA1*0102/ DQB1*0602 relatives identified on an initial sample as ICA-positive often manifest abnormalities in glucose tolerance. Protection from type 1 diabetes has been previously reported in a small number of antibody-positive DQB1*0602 relatives [8] [9] [10] . Our data suggest that DQA1*0102/DQB1*0602 does not provide protection from metabolic outcomes associated with the process of diabetes development (i.e. IGT/IFG), although this process may be somewhat atypical of type 1 diabetes. Indeed, we have shown that these subjects manifest a phenotype incorporating features of type 1 and type 2 diabetes. Specifically, the presence of autoantibodies commonly associated with type 1 diabetes and low first-phase insulin secretion are not associated with abnormalities of glucose tolerance among the DQB1*0602 relatives. A striking finding from our study is that these subjects had elevated fasting insulin levels. Elevated fasting insulin is often associated with the insulin resistance of type 2 diabetes. Indeed, HOMA-R, a measure of insulin resistance, was not only increased among the DQB1*0602-positive vs DQB1*0602-negative relatives, it was of a similar magnitude to that reported among type 2 patients [23] , and greater than that seen among adolescents [24, 25] . Interestingly, the marked difference in insulin resistance between the groups was not seen when BMI was tested, suggesting that obesity may not be the only factor contributing to the insulin resistance seen. Our data show that this high frequency of abnormal glucose tolerance was greater than that seen in the DQA1*0102/DQB1*0602-negative, but ICA-positive relatives. It is also greater than that seen in an older general population, where 22% of a cross-section of adults between 40 and 74 years had abnormal glucose tolerance or diabetes [26] .
Since these observations suggested that these subjects were atypical of the type 1 disease process, we explored the possibility that the proband in the family also manifested an unusual form of diabetes. Instead we found the expected HLA types among family members with diabetes, suggesting that the typical type 1 diabetes disease process is present in their families. To explore this question further, we also obtained information about the presence of diabetes in other family members. Among all the families, 22/68 reported diabetes in two generations and 2/68 in three generations. Though this proportion of multi-generation diabetes may suggest the possibility of MODY, it is important to keep in mind that DPT-1 selected for subjects with first-or second-degree relatives with diabetes and the number of multiplex families did not differ between the 0602-positive subjects and the 0602-negative matched control group (data not shown). In addition, neither the phenotype of abnormal glucose tolerance nor elevated fasting insulin identified families with distinct diabetes inheritance patterns. We also asked about the presence of type 2 diabetes in family members, since the insulin resistance suggested the possibility of co-existing type 2 diabetes genetic load. However, there was no increased frequency of type 2 diabetes among first-or second-degree family members by history (data not shown). Nevertheless, since type 2 diabetes is often not diagnosed, formal testing of this hypothesis requires metabolic testing of asymptomatic family members. This process, as well as HLA and autoantibody determination in these families is ongoing. Since it is difficult to propose a mechanism whereby HLA type in itself would affect insulin resistance, such an investigation can allow us to better understand the apparent relationship between DQB1*0602 and insulin resistance observed in this study.
Despite the high frequency of abnormal glucose tolerance in this group, it is still unknown whether these subjects will eventually progress to diabetes. Only two of those studied prospectively have diabetes according to OGTT criteria and associated with abnormal HbA 1 c, and as previously reported, only one additional subject has reported development of diabetes. Among subjects enrolled in the DPT-1 intervention trials, the presence of IGT results in an approximately 70% 5-year risk of type 1 diabetes, as determined from life-table analysis [11] . A similar high risk is seen among people with IGT and at risk for type 2 diabetes, with about 6% annual progression [27, 28] . It is possible that many of the DQA1*0102/ DQB1*0602 subjects with abnormal glucose tolerance will either never manifest overt diabetes, or will develop diabetes only later in life. Such a scenario would be consistent with data indicating that the relative protection of DQA1*0102/DQB1*0602 against the development of type 1 diabetes wanes with increasing age of diagnosis [29, 30] . Similarly, the frequency of high-risk alleles is decreased with increasing age at diagnosis [31, 32] . Alternatively, a slow progression of disease may result in patients being clinically classified as having type 2 diabetes or latent autoimmune diabetes of adults (LADA) [33] . In this regard, it is important to note that DQB1*0602 may not protect subjects from LADA, as one report has shown that these patients have the same frequency of this allele as seen in the general population [27] . Others report no differences in the frequency of highrisk alleles between LADA and older, but more typical type 1 patients [34] .
In this report, we have demonstrated for the first time that DQA1*0102/DQB1*0602 relatives of type 1 patients identified at screening as being ICA-positive have a high frequency of abnormal glucose tolerance, whether or not ICA was confirmed positive on a subsequent sample. The lack of association between these glucose abnormalities and markers of autoimmunity emphasises the fact that we cannot determine from this study whether the screening of family members for ICA detected a selected group of DQA1*0102/DQB1*0602 individuals, or whether the abnormal glucose tolerance is related to being an DQA1*0102/DQB1*0602 relative of an individual with type 1 diabetes per se. Further studies are planned to address this question. Nonetheless, the presence of this haplotype in these subjects does not provide dominant protection from metabolic outcomes associated with the diabetes disease process, although this process may be better characterised as atypical of type 1 diabetes and more resembling type 2 diabetes or LADA. Our data indicate that multiple pathways to abnormal glucose tolerance are present within families of type 1 diabetic patients. The increasing recognition that some patients of all ages with diabetes are not clearly classifiable as either type 1 or type 2 suggests that a new paradigm incorporating the relationship between insulin secretion and resistance may further our understanding of the disease process and allow for a wider range of therapeutic options before and after diagnosis.
